Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

09.01.2020 | short review | Ausgabe 1/2020

memo - Magazine of European Medical Oncology 1/2020

Importance of avoiding late cancer-directed therapy in terminally ill cancer patients

memo - Magazine of European Medical Oncology > Ausgabe 1/2020
MSc Dr. Daniela Jahn-Kuch
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


It is undeniably a great challenge to adequately weigh the benefits and harms of tumor-specific therapy near the end of life and to find the right time for changing the objective of therapy to palliative care alone. In a curative situation, the “survival” benefit of the treatment outweighs its potential harm due to side effects. However, things are different when the possibility of cure is ruled out. Important prerequisites to avoid overly zealous care are adequate communication about the therapeutic options and consensus between the doctor and the patient with regard to the (realistic) therapeutic goal, a realistic estimated prognosis and early integration of palliative care.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2020

memo - Magazine of European Medical Oncology 1/2020 Zur Ausgabe